The primary objective of this project is to establish an international anaplastic thyroid cancer tissue collection to help facilitate research opportunities. Patients also have the option to donate a blood sample and clinical data. 

The research proposals that subsequently arise as a result of this project will be generated by accredited research teams from the UK and internationally. Proposals will be accepted from academic and industry research parties. All research proposals will be submitted to the interNational Anaplastic Thyroid Cancer Tissue Bank and Database Project (iNATT) Steering Committee for assessment. The steering committee will be multidisciplinary and will include nationally respected researchers and thyroid cancer clinicians.

As the volume of material collected per patient is expected to be of small volume, by virtue of the specimen comprising core biopsy or fine needle aspirate material, research proposals will need to be prioritised according to the potential benefits the proposed research offers. Priority will be given to projects that may lead to the identification of potential therapeutic targets. Each research proposal will require ethical approval and the relevant research and development permissions prior to commencement.

ClinicalTrials.gov Identifier: NCT01774279

https://clinicaltrials.gov/ct2/show/NCT01774279?term=iNATT&rank=1

1. ATC patients will be identified by thyroid cancer specialists (including endocrine surgeons, head and neck cancer surgeons, clinical oncologists, endocrinologists, pathologists, radiologists, clinical nurse specialists) working in thyroid cancer multidisciplinary teams (MDTs) across the UK Cancer Networks and in international cancer centres.
2. Patients will be approached by a member of the MDT and provided with a patient information leaflet on the interNational Anaplastic Thyroid Cancer Tissue Bank and Database project. Following discussion and adequate time to consider the project, the patient will be invited to participate and to provide their informed consent.
3. It is expected that the majority of eligible patients will be willing to participate in this project as whilst their own care will be unchanged they will have the potential to help future patients with this rare disease. As entry into the project will not affect the patient's own care there is no time limit after diagnosis in which participation can be undertaken.
4. As ATC comprises a heterogeneous group of histological appearances that often prove difficult to accurately diagnose, a central pathological review process will be implemented to ensure uniform pathological reporting.
5. We have ethical approval to include patients retrospectively if they provided general consent for their tissue to be used in future research. We also have ethical approval to consider tissue donation from a qualifying relative, as defined by the Human Tissue Authority: Code of Practice 1: Consent, v14. July 2014. www.hta.gov.uk
6. We accept transfer of tissue from already established tissue collections held in cancer banks and biobanks nationally and  internationally.

• All patients with anaplastic thyroid cancer who are able to provide informed consent.
• Patients with foci of anaplastic thyroid cancer within a more differentiated thyroid cancer who are able to provide informed consent.

PDF File:    iNATT Patient Information - iNATT Patient Information Leaflet outlining the project